marijuana stock news

Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 9907568. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system, and on immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA (CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:
Annie Starr
6 Degrees
(973) 415-8838
astarr@6degreespr.com

INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
(212) 362-1200
Jane.Urheim@SternIR.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Zoned Properties, Inc. (ZDPY) CEO Bryan McLaren to Present at Upcoming Investor Conferences

Zoned Properties’ CEO Bryan McLaren to Present at Upcoming Investor Conferences Zoned…

$ENRT Closes First Tranche of Financing

Enertopia Closes First Tranche of Financing  Vancouver, BC / ACCESSWIRE / Jaunuary…

$XXII Registered Direct Offering: $6Million

22nd Century Group Announces $6 Million Registered Direct Offering CLARENCE, N.Y.–(BUSINESS WIRE)–…

MariMed, Inc. (MRMD) Strengthens Sales, Marketing, and R&D Teams With Senior Executive Hires

MariMed Strengthens Sales, Marketing, and R&D Teams With Senior Executive Hires MariMed,…